Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.


TSX:SZLS - Post by User

Comment by Onenessofall121on Jul 27, 2020 10:37am
94 Views
Post# 31323826

RE:LoboW2 and Onenessofall121 Reported

RE:LoboW2 and Onenessofall121 ReportedI didn't think I was saying anything bad really . Tripp holding them company a float with ColonSentry a bad thing ? He was using an inferior product to allow this company to get to the point that Aristotle dan be relevent ? Not an easy hill to climb . Quetion really is , why is Aristotle nit being embraced as a scientific break through product ? What is the resistance and why does it seem that it was expected ? Also , if you could give me your lean as to why this price is being held down due to lack of information on numbers they surely have by now ? What's the strategy do you figure ? 
<< Previous
Bullboard Posts
Next >>